Currently, Saxenda (Liraglutide - NVO) and Wegovy (Semaglutide - NVO) are the two GLP-1 drugs approved for weight loss by the FDA
The article suggests patients with high insulin resistance or evidence of GIPR-related glucose dysregulation may benefit from the dual-action agent, while those with milder insulin resistance and better GLP-1 pathway function may reach equivalent results on semaglutide, potentially with fewer gastrointestinal effects
By replenishing glutathione levels, your body's master detoxifier, NAC helps support long-term brain health, a balanced mood, stronger immunity, detoxification, and sharper focus, even in high-stress situations.*
and moderately reduce total cholesterol, low-density lipoprotein cholesterol, and triglycerides (82, 83) (Figure 2)